Intensive Immunosuppression in the Treatment of Multiple Sclerosis

Ring, Johannes; Lob, G.; Angstwurm, H; Brass, B; Backmund, H.; Seifert, J.; Coulin, Klaus; Frick, E.; Mertin, J.; Brendel, W.

doi:10.1016/s0140-6736(74)90866-6

Cited by 39 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…; a more elegant way is, however, the induction of immunological unresponsiveness against the xenogeneic globulin itself (6,12,19). There is evidence not only from animal experiments (2, 12, 18), but also from clinical studies (II, 16,17) that by this procedure the rapid elimination of ALG can be prevented thus leading to increased therapeutic efficacy as well as better compatibility.…”

Section: Discussionmentioning

confidence: 99%

Cumulation and elimination of horse-anti-dog lymphocyte and normal horse gammaglobulin in dogs

et al. 1976

View full text Add to dashboard Cite

Two groups of dogs received daily intravenous doses of 20 mg/kg 131-I-labelled horse-anti-dog lymphocyte globulin or normal horse gammaglobulin respectively over a period of 11 days. Horse-anti-dog lymphocyte globulin showed a significantly higher eleimination rate than normal horse gammaglobulin. In contrary to the continuous increase in serum radioactivity during normal horse gammaglobulin treatment, there was a plateau after the 5th day in the horse-anti-dog lymphocyte globulin group. The xenogeneic protein concentration, measured with the single radial immunodiffusion technique, at the end of treatment was 165 +/- 8 mg/1 in the horse-anti-dog lymphocyte globulin, compared to 498 +/- 15 mg/1 in the normal horse gammaglobulin group. After treatment horse-anti-dog-lymphocyte globulin treated animals showed a significantly higher increase in active hemagglutination titer against horse erythrocytes with an average of 2(-8).

show abstract

Section: Discussionmentioning

confidence: 99%

Cumulation and elimination of horse-anti-dog lymphocyte and normal horse gammaglobulin in dogs

et al. 1976

View full text Add to dashboard Cite

show abstract

“…Subsequent therapy with ALG was based on the theory that, particularly in ocular auto immune disease, cell-mediated immune reactions are pathogenically involved [9,23,27] and should respond to a substance like ALG that suppresses mostly the cellular immune response. This theory, together with the remarkable results achieved with ALG in other clinical conditions [2,3,28,40], encour aged our group to continue with this immunosuppressive therapy in selected ophthalmic patients.…”

Section: Introductionmentioning

confidence: 93%

“…However, the question of the efficacy of immunosuppression in so-called autoimmune diseases is unresolved, primarily because of the still unknown etiology of this group of immune disturbances. If one applies the strict criteria of Witebsky [52], there are only few true 'autoimmune' diseases in man, but one of them certainly is sympathetic ophthalmia [40,54], On the other hand, a number of clinical conditions are connected with abnormal immune reactions but have no proven autoimmune cause. The ophthalmic diseases, chronic uveitis and scleritis, belong to this group.…”

Section: Alg In Ocular Autoimmune Diseasementioning

confidence: 99%

Immunosuppression with Antilymphocyte Globulin (ALG) in the Treatment of Ophthalmic Disorders

Ring¹,

Dechant²,

Seifert³

et al. 1978

Ophthalmic Res

View full text Add to dashboard Cite

Immunosuppression with antilymphocyte globulin (ALG) was administered to 13 patients suffering from ophthalmic diseases. These included 4 with sympathetic ophthalmia, 3 with chronic generalized uveitis, 1 with necrotizing scleritis, 3 with corneal transplantation and 2 with combined corneal and scleral transplants. There was significant improvement in the patients with sympathetic ophthalmia and uveitis when ALG treatment was started early enough, i.e., as long as inflammatory processes were demonstrable. The results achieved in patients given corneal transplants were less convincing in the final outcome, although 3 patients – 2 had rejected previous corneal grafts within weeks – tolerated their corneas for several months after ALG treatment. It was not possible to reverse opacification occurring during corneal graft failure by ALG

show abstract

“…The reported benefit to M.S. patients treated with intensive immunosuppression (Brendel et al, 1975;Ring et al, 1974;Ring et al, 1976) and the lack of information on long term effects of ATG prompted a re-evaluation of M.S. patients treated with this medication.…”

mentioning

confidence: 99%

Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up

1978

Can. j. neurol. sci.

View full text Add to dashboard Cite

SUMMARY:Multiple sclerosis patients treated with antithymocyte globulin (ATG) were re-evaluated after five years. No long term benefit was found. Notably, the group of patients with an elevated gamma globulin to total protein ration in their C.S.F. and who did particularly well after treatment with ATG also failed to show any long term benefit. Few long term detrimental effects of ATG immunosuppression were identified. The implications of the results are discussed as they relate to the use of immunosuppression in multiple sclerosis.

show abstract

Intensive Immunosuppression in the Treatment of Multiple Sclerosis

Cited by 39 publications

References 18 publications

Cumulation and elimination of horse-anti-dog lymphocyte and normal horse gammaglobulin in dogs

Cumulation and elimination of horse-anti-dog lymphocyte and normal horse gammaglobulin in dogs

Immunosuppression with Antilymphocyte Globulin (ALG) in the Treatment of Ophthalmic Disorders

Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up

Contact Info

Product

Resources

About